Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases
Status:
Completed
Trial end date:
2020-11-11
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn more about how the study drug alpharadin
(Radium-223) works in patients who have CPRC that has spread to the bone.